Here, we repurpose the thromboxane A2-prostanoid receptor (TPr) inhibitor, ifetroban, to block platelet-tumor cell interactions and reduce metastasis in models of triple negative breast cancer (TNBC). The gene discussed is TPR; the disease is triple-negative breast carcinoma.